Madrigal outlines 2027 F4c outcomes readout while reinforcing mid- to high 30s 2026 gross-to-net outlook (NASDAQ:MDGL)
Earnings Call Insights: Madrigal Pharmaceuticals (MDGL) Q2 2026 Management View "Second quarter 2026 net sales were $364 million, representing year-over-year ...
